Huberman Lab

Dr. Natalie Crawford on Huberman Lab: Why AMH drops early

Tracking ovulation and testing AMH early flags fertility reserve loss; meiosis errors, luteal defects, and inflammation compound age effects on fertility.

NCDr. Natalie CrawfordguestAHAndrew Hubermanhost

Apr 13, 2026·2h 36m·Watch on YouTube ↗

📖 CHAPTERS

1. 1

   Dr. Natalie Crawford’s framework: fertility as a window into whole-body health

   Huberman introduces Dr. Natalie Crawford and frames fertility as more than pregnancy—it's a marker of hormonal, metabolic, and cellular health. Crawford explains how infertility often correlates with broader health risks, not because it directly causes them, but because it can be an early warning sign of underlying inflammation or insulin resistance.

2. 2

   Perimenopause & menopause: redefining ovarian aging and hormone therapy timing

   Crawford explains perimenopause as a long transition where cycle changes and hormone symptoms can begin years before the traditional menopause definition. She and Huberman discuss why waiting for strict cutoffs (e.g., 12 months without a period) can delay helpful care and how hormone therapy is increasingly viewed as beneficial when appropriately timed.

3. 3

   Extending ovarian function: inflammation, autoimmune disease, and lifestyle leverage points

   The conversation shifts to what might influence ovarian lifespan beyond genetics, emphasizing inflammation and autoimmune associations with earlier ovarian insufficiency. Crawford outlines how managing inflammatory conditions and lifestyle choices could plausibly slow ovarian aging, even if definitive trials are limited.

4. 4

   Plastics, microplastics & endocrine disruption: what’s known and what to do

   Crawford addresses concern about plastics and endocrine-disrupting chemicals, emphasizing practical risk reduction rather than perfectionism. She highlights observational links between certain exposures and worse fertility/IVF outcomes while acknowledging confounding factors and the importance of cumulative exposure.

5. 5

   Prior pregnancy, secondary infertility, and why earlier testing matters (including sperm)

   Crawford reviews data showing prior live birth can improve fecundability (month-to-month pregnancy probability) for a time, but secondary infertility is real and emotionally complex. She strongly argues against the “fail-first” model and emphasizes early evaluation—especially semen testing—to prevent wasted time.

6. 6

   Pregnancy loss, termination, and conceiving again: evaluation thresholds and uterine health

   Crawford discusses pregnancy loss compassionately, including her personal experience, and explains how loss can still indicate some intact fertility pathways while requiring timely evaluation. She clarifies that abortion/termination doesn’t inherently cause infertility, but any intrauterine procedure can carry scarring risk, especially with infection or heavy bleeding.

7. 7

   Core reproductive biology: egg number vs egg quality and how the menstrual cycle works

   Crawford gives a detailed, practical explanation of ovarian physiology: women are born with their egg supply, eggs leave the ‘vault’ each month, and ovulation depends on FSH/LH and estrogen/progesterone signaling. She distinguishes egg quantity (reserve) from egg quality (genetic normalcy/competency) and explains why age is an imperfect proxy for quality.

8. 8

   Tooling for planning: AMH testing, what it means, and why Crawford recommends it broadly

   Crawford argues most women who might want children should get an AMH (anti-Müllerian hormone) test to understand ovarian reserve, despite professional guidelines discouraging it absent infertility. She explains what AMH can and cannot tell you, why low AMH prompts investigation for root causes, and how the information changes decision-making.

9. 9

   Ovulation tracking as a health marker: luteal phase defects and hidden ovulatory problems

   Beyond ‘regular periods,’ Crawford emphasizes tracking ovulation to detect subtle dysfunction earlier. She explains how ovulatory disorders often begin with luteal phase shortening, then progress into delayed ovulation and irregular cycles—patterns that may be missed if someone tracks only bleeding dates.

10. 10

    Egg freezing & IVF realities: what it does (and doesn’t) do to ovarian reserve + ethical considerations

    Crawford debunks the myth that egg freezing or IVF causes earlier menopause; stimulation simply rescues eggs that would otherwise undergo natural attrition that month. She also discusses embryo vs egg freezing, attrition rates from egg to live birth, embryo disposition concerns, and the policy/insurance landscape.

11. 11

    Hormonal birth control and return to fertility: pill vs IUD vs Depo-Provera

    Crawford explains that large studies don’t show higher long-term infertility rates after contraception, but specific methods can delay optimal conception timelines. She highlights the short half-life of the pill, the endometrial rebuilding period after progesterone IUD removal, and Depo-Provera’s uniquely prolonged ovulation suppression in some people.

12. 12

    Lifestyle & supplement protocol for “trimester zero”: inflammation, sleep, NSAIDs, and key supplements

    Crawford lays out actionable “do, don’t do, and take” principles for improving egg/sperm quality, emphasizing sleep and overall inflammatory load. She warns that anti-inflammatory NSAIDs can prevent follicle rupture around ovulation, discusses melatonin dosing nuance, and outlines commonly used preconception supplements with better evidence.

13. 13

    Emerging and debated interventions: red light, GLP-1s for endometriosis, HGH, PRP, and paternal age

    The episode closes with a tour of newer or less-settled tools and risk factors. Crawford discusses promising-but-inconclusive areas like red light therapy, GLP-1 agonists for inflammatory infertility/endometriosis (independent of weight loss), add-ons such as HGH in IVF, PRP approaches, and advanced paternal age risks.

14. 14

    Behavioral toxins & everyday endocrine disruptors: cannabis, nicotine, fragrances, receipts, and biotin lab interference

    Crawford highlights high-impact exposures that are modifiable and often underestimated. She details strong associations between cannabis and impaired sperm/egg outcomes, addresses nicotine’s harms (especially via smoking data), explains how fragrance/thermal receipts can increase endocrine disruptor exposure, and warns that biotin can distort hormone lab results.